describe the immunomodulatory mechanism of action of daratumumab, and discuss the clinical efficacy and safety/tolerability of daratumumab-based combination therapies in the treatment of patients with relapsed or refractory multiple myelom

Using the 3 articles available at the links below, please describe the immunomodulatory mechanism of action of daratumumab, and discuss the clinical efficacy and safety/tolerability of daratumumab-based combination therapies in the treatment of patients with relapsed or refractory multiple myeloma. Assume that this brief review-type article will be submitted for publication in a hematology journal and that the target audience is hematologists/oncologists. You do not need to include the content of the supplementary appendices that accompany these publications.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957162/

https://www.nejm.org/doi/pdf/10.1056/NEJMoa1606038

https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607751

Note, for the 2 NEJM articles above, you may need to create a free user account with the journal in order to download the content.

Please consider the following during the preparation of your writing sample:

• Limit your writing sample to no more than 3 double-spaced pages (not including figures, tables, and references)
• Use only the references included as source material (ie, for the purposes of this exercise, there is no need to cite the primary references used in the source material)
• Include tables and figures as appropriate
• Reference the writing sample as appropriate – AMA format